The Mr. Green bodega sits on a busy stretch of Bedford Avenue in Brooklyn, New York, where the sidewalk is a constant jostle of dog walkers, strollers, and people who have just gotten off the L train. It looks like any other corner store: fluorescent light spills onto the pavement, a refrigerated case hums near the door, and the shelves are packed with the usual bodega inventory—candy, gum, chips, rolling papers, and soda. But near the counter, among the everyday convenience-store miscellany, there is a small display that catches the eye. Tiny glass vials, neat and clinical, sit alongside the cigarettes. They contain peptides, a broad class of amino acids that have become enormously popular for their supposed ability to help with everything from weight loss and muscle recovery to low libido and cellular repair. The sign above the display says “research use only,” which sounds more like a disclaimer than an invitation. But the clerk behind the counter was perfectly happy to sell us four different kinds. We paid $376.20 and left with an unlabeled paper bag containing vials labeled PT-141, BPC-157, NAD+, and retatrutide. Mr. Green was one of several shops that went viral this summer for selling peptides, and we wanted to know what was actually inside those tiny vials. So we did what any curious customer with access to an independent testing company might do: we bought them, packed them up, and sent them to a lab.
The lab in question belongs to Finnrick, an Austin-based startup that acts as a kind of middleman for peptide testing. Finnrick doesn’t have its own in-house laboratory; instead, it connects ordinary people with accredited labs that can analyze their samples. For a fee, consumers can request tests for purity, check for common contaminants like heavy metals and endotoxins, and verify whether a vial contains the quantity of the substance listed on the label. It’s a service that sounds niche, but in the current peptide gold rush, it’s exactly the kind of due diligence that regulators and doctors wish more people would do before injecting themselves with things bought from a corner store. The process is straightforward: you send in your vials, fill out a chain-of-custody form, and wait. Finnrick’s CEO, Raphaël Mazoyer, told us that the company has been growing quickly as more people become curious about what they’re actually buying. We were curious too. After all, peptides have been marketed as a kind of biomedical miracle—compounds that can supposedly repair tissue, boost metabolism, restore energy, and reverse aging. Some of them, like the GLP-1 drugs that have transformed the weight-loss industry, are legitimate pharmaceutical products. But many of the peptides that have flooded the market exist in a strange legal and scientific gray zone. They are sold for “research purposes,” not for human consumption, even though everyone knows that the people buying them are planning to inject them into their own bodies. That disconnect is exactly what makes independent testing so important. We sent our vials off in the mail and settled in to wait.
A few weeks later, in August, the results came back. The news was mixed, and in some ways more confusing than a simple yes or no. The relatively good news was that our samples contained low levels of heavy metals and endotoxins. That may sound alarming, but in the world of unregulated injectable products, it was actually a relief. Endotoxins are bacterial toxins that can cause fevers and severe immune reactions, and heavy metals can accumulate in the body and cause long-term damage. The fact that our vials were relatively clean meant that they probably weren’t actively harmful in the way that some contaminated black-market drugs are. But then came the bad news. The samples did not contain the peptides listed on their labels. The vial labeled BPC-157, which is supposed to promote healing and muscle recovery, contained no BPC-157 at all. The same was true for the other three vials. The test results were negative across the board, meaning that whatever was in those little glass containers, it wasn’t what we had paid for. The vials could have been mislabeled from the start, or they could have contained the correct ingredients at some point and then degraded into something unrecognizable. Peptides are notoriously sensitive. They often need to be refrigerated, and even brief exposure to heat or improper handling can break them down. A bodega shelf is not exactly a temperature-controlled pharmaceutical storage facility. Marco Krause, the CEO of the laboratory that performed the tests for Finnrick, explained the limits of what his team could tell us. “What we offer is simply a label claim analysis,” he said. “So you send us what you claim to think it is, and then we run it against a standard and verify whether or not it’s the right compound.” In other words, the lab could confirm that the substance we thought we had was absent, but it couldn’t necessarily tell us what had replaced it.
That ambiguity is a central feature of the modern peptide boom. Over the past few years, peptides have been propelled from obscure bodybuilding forums to the mainstream by a strange coalition of influencers, podcasters, and public figures. United States Health Secretary Robert F. Kennedy Jr. has talked about their potential. Joe Rogan has hosted long conversations about them on his massively popular podcast. The result is a culture in which peptides are discussed with the kind of breathless enthusiasm once reserved for vitamins or nootropics, but with far less oversight. Some peptides are pharmaceutical drugs, like the GLP-1 agonists that millions of people now take for diabetes and weight loss. But many of the buzziest peptides have never gone through the typical regulatory approval process. They have not been proven safe and effective in large clinical trials. They have not been reviewed by the FDA. In many cases, they are not even legally allowed to be sold for human consumption in the United States. That is why they are labeled “for research use only.” The label is a legal shield, a way for sellers to avoid responsibility if something goes wrong. But as our test results showed, it’s a shield that protects the seller, not the buyer. There is no guarantee that the vial contains what the label says, no guarantee that it is sterile, no guarantee that it was manufactured in a facility with any quality control at all. The person injecting it is the one taking all the risk.
When we shared our results with Raphaël Mazoyer, the CEO of Finnrick, he wasn’t surprised. He described our samples as “just duds.” Over the past three months, he said, his company had seen an uptick in exactly this kind of result. He couldn’t say for certain what was driving the trend—part of it might simply be that Finnrick is testing more samples as its business grows—but he pointed to a troubling pattern in the peptide supply chain. A growing number of so-called turnkey services now make it possible for almost anyone to start a peptide brand. These services provide everything: the vials, the labels, the packaging, even the website. You don’t need a background in chemistry or a relationship with a licensed manufacturer. You just need a brand name and a payment processor. The problem is that many of these brands are drawing from the same upstream vendors. “There are a whole bunch of labels popping up that have the same upstream vendor,” Mazoyer said. That means the same questionable supplier could be providing products to dozens of different companies, each selling under its own brand name. Some of the products that Finnrick tests are legitimate, Mazoyer stressed. But the structure of the industry makes it easy for bad actors to hide. A peptide company can look professional online, with sleek packaging and impressive marketing copy, while its products are little more than mystery liquid in a vial. For consumers, the implications are serious. Injecting a substance that has not been properly tested is risky enough when you know what it is. Injecting a substance that may not contain any of the active ingredient on the label is a gamble with even worse odds.
In the end, our trip to Mr. Green was a small experiment, but it revealed something much larger about the state of health and wellness in America. The same forces that have made peptides so popular—the distrust of traditional medicine, the hunger for quick fixes, the influence of social media—have also created a market where the line between medicine and merchandise has all but disappeared. A bodega in Brooklyn can sell injectable compounds alongside candy and soda, and the only thing standing between the buyer and harm is a vague warning about research use. Independent testing services like Finnrick are trying to fill the gap, giving consumers at least a fighting chance to know what they’re putting into their bodies. But testing has its limits. A label claim analysis can tell you whether a specific substance is present, but it can’t identify every unknown compound that might be in the vial. It can’t tell you whether the manufacturing process was sterile. It can’t tell you whether the product was stored properly before it reached the shelf. And it can’t tell you whether the peptide, even if genuine, actually works for the condition you’re trying to treat. What our results made clear is that the peptide boom is running far ahead of the science, the law, and the safety net. There is real hope embedded in some of these compounds, and real potential for future treatments. But for now, the experience of buying peptides at Mr. Green feels less like a medical transaction and more like a game of roulette. The clerk didn’t ask us what we were going to do with the vials. He didn’t offer any advice about dosage or storage. He just took our money, put the vials in a paper bag, and sent us out into the busy Brooklyn afternoon. We walked away with our mystery samples, and the lab later confirmed what we had begun to suspect: in the wild west of peptides, the label is just the beginning of the story—and often, it’s a lie.
